![Taltz 80 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc) Taltz 80 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc)](https://www.medicines.org.uk/emc/images/spc/spc~32054~14~image4.png)
Taltz 80 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc)
![Taltz 80 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc) Taltz 80 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc)](https://www.medicines.org.uk/emc/images/spc/spc~32054~14~image24.png)
Taltz 80 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc)
![Long‐term efficacy and safety results from an open‐label phase III study (UNCOVER‐J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab - Umezawa - 2019 - Journal of Long‐term efficacy and safety results from an open‐label phase III study (UNCOVER‐J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab - Umezawa - 2019 - Journal of](https://onlinelibrary.wiley.com/cms/asset/4d29e6d9-c55c-4c6c-bd56-be17ee5dd35b/jdv15292-fig-0001-m.jpg)
Long‐term efficacy and safety results from an open‐label phase III study (UNCOVER‐J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab - Umezawa - 2019 - Journal of
![Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials | SpringerLink Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13555-020-00367-x/MediaObjects/13555_2020_367_Fig1_HTML.png)
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials | SpringerLink
![PDF] Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience | Semantic Scholar PDF] Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/8475108e210007edf6f24a80c253692db913891f/2-Figure1-1.png)
PDF] Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience | Semantic Scholar
![PDF) Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: Results from the randomised, controlled and open-label phases of UNCOVER-3 PDF) Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: Results from the randomised, controlled and open-label phases of UNCOVER-3](https://www.researchgate.net/profile/Phoebe-Rich/publication/309723691/figure/fig1/AS:725236093825029@1549921167931/Mean-per-cent-NAPSI-change-from-baseline-panel-a-Percentage-of-patients-achieving_Q320.jpg)
PDF) Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: Results from the randomised, controlled and open-label phases of UNCOVER-3
![LB0005 MULTICENTRE, RANDOMISED, OPEN-LABEL, ASSESSOR-BLINDED, PARALLEL-GROUP HEAD-TO-HEAD COMPARISON OF THE EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS ADALIMUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS NAIVE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC ... LB0005 MULTICENTRE, RANDOMISED, OPEN-LABEL, ASSESSOR-BLINDED, PARALLEL-GROUP HEAD-TO-HEAD COMPARISON OF THE EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS ADALIMUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS NAIVE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC ...](https://ard.bmj.com/content/annrheumdis/78/Suppl_2/261/F2.large.jpg)
LB0005 MULTICENTRE, RANDOMISED, OPEN-LABEL, ASSESSOR-BLINDED, PARALLEL-GROUP HEAD-TO-HEAD COMPARISON OF THE EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS ADALIMUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS NAIVE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC ...
![These highlights do not include all the information needed to use TALTZ safely and effectively. See full prescribing information for TALTZ.TALTZ ( ixekizumab) injection, for subcutaneous useInitial U.S. Approval: 2016 These highlights do not include all the information needed to use TALTZ safely and effectively. See full prescribing information for TALTZ.TALTZ ( ixekizumab) injection, for subcutaneous useInitial U.S. Approval: 2016](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=taltz-carton-pfs-025-04.jpg&id=610346)
These highlights do not include all the information needed to use TALTZ safely and effectively. See full prescribing information for TALTZ.TALTZ ( ixekizumab) injection, for subcutaneous useInitial U.S. Approval: 2016
![Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA) Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)](https://mma.prnewswire.com/media/661014/Eli_Lilly_Logo.jpg?p=facebook)
Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
![Figure 1. | Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis | The Journal of Rheumatology Figure 1. | Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis | The Journal of Rheumatology](https://www.jrheum.org/content/43/2/289/F2.medium.gif)
Figure 1. | Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis | The Journal of Rheumatology
![Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial - The Lancet Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9b996016-dd72-4ddd-a43d-473a0a0c00d4/gr2_lrg.jpg)
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial - The Lancet
![Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis - ScienceDirect Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S019096221830505X-gr3.jpg)
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis - ScienceDirect
![Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis - Journal of the American Academy of Dermatology Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis - Journal of the American Academy of Dermatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/dca853d0-b2f8-47bf-bb63-1b99b166b46c/gr1.jpg)
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis - Journal of the American Academy of Dermatology
![Study design for administration of ixekizumab via a prefilled syringe... | Download Scientific Diagram Study design for administration of ixekizumab via a prefilled syringe... | Download Scientific Diagram](https://www.researchgate.net/publication/306004096/figure/fig2/AS:393198137561090@1470757149098/Study-design-for-administration-of-ixekizumab-via-a-prefilled-syringe-or-autoinjector.png)
Study design for administration of ixekizumab via a prefilled syringe... | Download Scientific Diagram
![Fillable Online accessdata fda LABEL. TALTZ (ixekizumab) injection, Eli Lilly and Company - accessdata fda Fax Email Print - pdfFiller Fillable Online accessdata fda LABEL. TALTZ (ixekizumab) injection, Eli Lilly and Company - accessdata fda Fax Email Print - pdfFiller](https://www.pdffiller.com/preview/101/261/101261840.png)